Skip to content
lifestyle.celebhomes.net
Author:
Prelude Therapeutics, Incorporated
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
September 10, 2026
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
April 20, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
April 20, 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
April 15, 2026
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
March 10, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
February 3, 2026